louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03115008: Improving Competency and Metrics for PoLypectomy Skills Using Evaluation Tools and VidEo Feedback (COMPLETE)
Official title: Training for COMPLETE Polyp Resection During Colonoscopy -Improving Competency and Metrics for PoLypectomy Skills Using Evaluation Tools and VidEo Feedback
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Lead sponsor: San Francisco Veterans Affairs Medical Center
Sponsor class: FED
Collaborators: name: University of Colorado, Denver
name: Colorado Clinical & Translational Sciences Institute
name: University of Kansas Medical Center
First posted: 2017-04-14
Enrollment: 22
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: I plan to investigate the value of video-based feedback in endoscopic training - specifically, the role of terminal video feedback as compared to usual concurrent feedback on cold snare polypectomy technique in trainees, using Direct Observation of Polypectomy Skills (DOPyS) competency score. I have focused the study on the competency of cold snare polypectomy for subcentimeter polyps. The majority (\>75%) of colon polyps are smaller than one centimeter. Cold snare polypectomy has been shown, and recommended by the American Society for Gastrointestinal Endoscopy (ASGE), to be an effective removal technique. However, its widespread use and moreover, its teaching to trainees is lacking. It takes time and resources to learn and teach endoscopic techniques. Our study will hope to identify a mechanism through video-based feedback that could help to improve the translation of the training of polypectomy skills to its actual performance, and to accelerate the learning curve.


Eligibility criteria: Inclusion Criteria:

* Participants: Senior level UCSF gastroenterology trainees (2nd and 3rd year GI fellows) rotating at the San Francisco Veterans Affairs Medical Center (SFVAMC).
* Patients undergoing elective routine colonoscopy procedure.

Exclusion Criteria:

* Participants: Junior level University of California, San Francisco (UCSF) gastroenterology trainees (1st year GI fellows) rotating at the San Francisco Veterans Affairs Medical Center, and senior level trainees who are not rotating at the SFVAMC.
* Patients: Patients undergoing undergoing emergency colonoscopy procedure.

Primary outcomes:
measure: Number of polypectomies for gastroenterology trainees to achieve competency
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: San Francisco VA Medical Center
state: California
Study officials:
References:
Clinical trial NCT00349908: A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries
Official title: A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Atherosclerosis
Aneurysm
Keywords: Atherosclerosis,Wide Neck Aneurysm
Lead sponsor: Codman & Shurtleff
Sponsor class: INDUSTRY
First posted: 2006-07-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Feasibility study to assess safety of treating patients with self expanding stent in intracranial arteries.

Detailed description: Feasibility study to assess safety of treating patients with self expanding stent in intracranial arteries. Patients will be followed for 6 months with assessments related to technical feasibility and adverse events.

Eligibility criteria: Contact site for specific information

Inclusion Criteria:

* Subject meet specific criteria for treatment
* Subject must be willing to return to site for 30 day and 6 month follow up evaluations

Exclusion Criteria:

* Stenting, angioplasty or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to expected enrollment date
* Previously implanted carotid stent associated with the symptomatic distribution within the past 12 weeks

Primary outcomes:
measure: Technical Feasibility- Successful Stent/Coil Placement (Post Procedure)
timeFrame: post procedure
measure: Technical Feasibility- Percent Occlusion (Post Procedure)
timeFrame: post procedure
measure: Technical Feasibility- Percent Occlusion (6 Mo Post Procedure)
timeFrame: 6 mo
measure: Technical Feasibility- Successful Stent/Coil Placement (6 Mo Post Procedure)
timeFrame: 6 mo
measure: Technical Feasibility- Percent Stenosis (6 mo Post Procedure)
timeFrame: 6 mo
measure: Technical Feasibility- Percent Stenosis (Post Procedure)
timeFrame: Post Procedure
Secondary outcomes:
measure: The Secondary Outcome Measure in Group 1, Atherosclerosis and in Group 2, Aneurysm, is the Evaluation of Adverse Events. The Groups Were Analyzed Separately.
timeFrame: 6 months
Other outcomes:
Locations:
city: Belgrano
country: Argentina
facility: Eneri-Clinica Adventista Belgrano
Study officials:
affiliation: ENERI-CLINICA ADVENTISTA BELGRANO
name: Pedro Lylyk, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02864108: The Crnic Institute Human Trisome Project Biobank
Official title: Research to Develop the Human Trisome Project Biobank
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Down Syndrome
Trisomy 21
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: Linda Crnic Institute for Down Syndrome
name: National Center for Advancing Translational Sciences (NCATS)
name: GLOBAL Down Syndrome Foundation
name: Anna and John J. Sie Foundation
First posted: 2016-08-11
Enrollment: 2500
Sex: ALL
Minimum age (years): 6
Maximum age (years): 89
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with Down syndrome, individuals related to someone with Down syndrome or of the general population who do not have a relationship to Down syndrome.

Brief summary: The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.

Detailed description: The purpose of this study is to provide qualified and approved researchers with access to biological samples and health information to answer specific research questions. This project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions such as Alzheimer's disease, congenital heart defects, autoimmune disorders, autism, and some forms of leukemia.

Participation includes a blood draw, a mouth swab, and allowing researchers to look at your health information yearly for the next 5 years. Optional procedures include providing a urine and/or stool sample and taking part in the study for a longer time frame.

Eligibility criteria: Inclusion Criteria:

Anyone 6 months to 89 years old who:

1. has Down syndrome (any type)
2. does not have Down syndrome

Exclusion Criteria:

1. Prisoners
2. Wards of the state

Primary outcomes:
measure: Number of Participants and Controls Enrolled in Biobank
timeFrame: 5 years
Secondary outcomes:
measure: Number of Clinical Records Available for Approved Research Purposes
timeFrame: 5 years
measure: Multidimensional Sample Characterization
timeFrame: 5 years
Other outcomes:
Locations:
city: Denver
country: United States
facility: Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
state: Colorado
Study officials:
affiliation: Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
name: Joaquin Espinosa, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, Khanal S, Butcher ET, Estrada BE, Rachubinski AL, McWilliams JA, Minter R, Dimasi T, Colvin KL, Baturin D, Pham AT, Galbraith MD, Bartsch KW, Yeager ME, Porter CC, Sullivan KD, Hsieh EW, Espinosa JM. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Rep. 2019 Nov 12;29(7):1893-1908.e4. doi: 10.1016/j.celrep.2019.10.038.
Clinical trial NCT03384108: In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells
Official title: In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells in Healthy Subjects Using Stable Isotope Resolved Metabolomics: A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-12-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In Vivo vs. Ex Vivo assessment of 5-13C-Glutamine incorporation by plasma cells via a bone marrow aspiration.
Primary purpose: DIAGNOSTIC

Brief summary: This pilot study will first establish the feasibility of an in vivo methodology of assessing the utilization of glutamine into the TCA cycle of normal bone marrow plasma cells from healthy subjects while comparing it to an ex vivo approach

Detailed description: Twenty healthy adult study participants between the ages of 18 and 60 years will be recruited to participate in this pilot study that will include two groups: a) Ex Vivo group (10 volunteers) and b) In Vivo group (10 volunteers). Volunteers will be recruited to either group in a sequential alternating fashion.

In vivo 13C SIRM studies evaluating the utilization of glutamine into the TCA cycle of normal bone marrow plasma cells.

Eligibility criteria: Inclusion Criteria:

* Ages 18-60
* Able to provide written consent

Exclusion Criteria:

* Renal Failure
* Pregnancy
* Active steroid use
* Active liver Disease
* Anemia (Hemoglobin \< 12.5 g/dL in men and \< 11.5 g/dL in women)
* H/O alcohol use (average \> 2 drinks per day)
* BMI \> 30

Primary outcomes:
measure: Percentage of enrichment of 13-Carbon molecules in the TCA cycle metabolites of plasma cells measured by gas chromatography mass spectrometry.
timeFrame: Through study completion, an average of 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Wilson Gonsalves, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, Pettersson XM, Bush AG, Gransee J, Anderson EI, Kumar SK, Nair KS. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab. 2020 Dec 11;8(1):29. doi: 10.1186/s40170-020-00235-4.
Clinical trial NCT06765408: Effect of Face Yoga on Mimic Muscles
Official title: The Effect of Facial Yoga on Tonus, Stiffness and Elasticity of Mimic Muscles
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Facial Yoga
Facial Exercises
Keywords: facial yoga
Myoton
tonus
stiffness
elasticity
Lead sponsor: Bandırma Onyedi Eylül University
Sponsor class: OTHER
First posted: 2025-01-09
Enrollment: 20
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy female volunteers

Brief summary: This study aimed to investigate the effect of facial yoga on tonus, stiffness and elasticity of facial muscles.

Detailed description: This study was conducted on healthy volunteers aged 25-50 between June 2024 and January 2025. In the participants who agree to participate in the study, a descriptive data form and myotone evaluations of facial muscles will be performed. Measurements will be carried out immediately after the participants are recruited and at the end of the 8-week facial yoga programme.

Eligibility criteria: Inclusion Criteria:

* Individuals between 25-50 years of age whose voluntary consent was obtained

Exclusion Criteria:

* Botox application to the facial area in the last 6 months,
* Regular use of analgesics and anti-inflammatories,
* The presence of infection or tumoural structures within the structures in the facial region,
* With TMJ disc displacement and joint degeneration,
* Cervical or TMJ fracture, systemic disease, musculoskeletal problem with evidence of specific pathological condition,
* Any surgical operation related to cervical or TMJ problem,
* Less than 6 months of cervical or TMJ-related physiotherapy and rehabilitation services,
* The one with facial paralysis,
* Participants with diagnosed psychiatric illness will not be included in the study.

Primary outcomes:
measure: Evaluation of the mimic muscles tone
timeFrame: June 2024- August 2024
measure: Evaluation of the mimic muscles stiffness
timeFrame: June 2024- August 2024
measure: Evaluation of the mimic muscles elasticity
timeFrame: June 2024- August 2024
Secondary outcomes:
measure: Assessing mimic muscle tone after exercising
timeFrame: October 2024- December 2024
measure: Assessing mimic muscle stiffness after exercising
timeFrame: October 2024- December 2024
measure: Assessing mimic muscle elasticity after exercising
timeFrame: October 2024- December 2024
Other outcomes:
Locations:
city: Balikesir
country: Turkey
facility: Bandırma Onyedi Eylül University
Study officials:
References:
Clinical trial NCT02901808: Registeranalysis for the Examination of NOMI
Official title: Interdisciplinary Retrospective Registeranalysis for the Examination of Non-occlusive Mesenteric Ischemia (NOMI)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mesenteric Ischemia
Keywords: NOMI
Angiography
Digital Subtraction Angiography (DSA)
Lead sponsor: Universität des Saarlandes
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 10000
Sex: ALL
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cardio-thoracic surgical patients

Brief summary: The registry includes patients undergoing cardiovascular and thoracic surgery at the Saarland University Medical Center, Homburg/Saar, Germany. This study is a monocentric, retrospective study investigating the development of NOMI and outcome of patients.

Detailed description: All data were acquired from the hospital electronic health record and the picture archiving computer system (PACS).

NOMI was suspected if the following clinical signs occured:

new onset of oliguria (urine output \<0.5 mL/kg/hour for at least 6 hours) or anuria, abdominal distention with decreased or absent bowel sounds, elevated serum lactate levels \>5.0mmol/L or metabolic acidosis (base excess \<-5mmol/L).

In accordance to the definition of cardiogenic shock angiography was performed in patients with a systolic blood pressure \>90 mmHg and a cardiac index \>1.8 L/minute/m².

Eligibility criteria: Inclusion Criteria:

* The investigators include anonymous data from patients with cardio-thoracic surgery

Exclusion Criteria:

* None

Primary outcomes:
measure: Development of NOMI
timeFrame: at the day of surgery, day zero
Secondary outcomes:
measure: Length of stay
timeFrame: at the day of surgery, day zero up to 365 days
measure: Mechanical ventilation
timeFrame: at the day of surgery, day zero up to 365 days
measure: Mortality
timeFrame: at the day of surgery, day zero up to 365 days
Other outcomes:
Locations:
city: Homburg
country: Germany
facility: Saarland University Medical Center
state: Saarland
Study officials:
affiliation: Department of Diagnostic and Interventional Radiology
name: Arno Buecker, MD
role: STUDY_DIRECTOR
affiliation: Department of Thoracic and Cardiovascular Surgery
name: Hans-Joachim Schäfers, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05101408: Executive Training and Anomia Therapy in Chronic Post-stroke Aphasia
Official title: Combining Executive Training and Anomia Therapy in Chronic Post-stroke Aphasia : a Single Case Experimental Design -SCED Preliminary Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anomia
Post-stroke Aphasia
Keywords: Aphasia
Speech-Language Therapy
Anomia
Executive functions
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-11-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Person with post-stroke aphasia at the chronic stage, receiving SLT rehabilitation

Brief summary: Aphasia is a devastating acquired language impairment mainly caused by stroke, in which anomia is a quintessential clinical feature. If speech-language therapy (SLT) has been shown to be effective for persons with aphasia, the relative efficiency of one SLT strategy over another remains a matter of debate. The influential relationship between language, executive functions and aphasia rehabilitation outcomes has been addressed in a number of studies, but only few of them have studied the effect of adding an executive training to linguistic therapies.The aim of this study is to measure the efficiency of a protocol combining anomia therapy and executive training on naming skills and discourse in post-stroke aphasic persons at the chronic stage


Eligibility criteria: Inclusion criteria:

* 18 \< age \> 80 years
* adult person with chronic post-stroke aphasia (\> 6 months postonset)
* receiving SLT rehabilitation 3 times a Week

Exclusion criteria:

* presence of apraxia of speech
* major impairment of comprehension
* history of other neurological or psychiatric disease

Exclusion criteria:

* presence of apraxia of speech
* presence of major impairment of comprehension
* presence of history of other neurological or psychiatric disease

Primary outcomes:
measure: Evolution of individual naming scores
timeFrame: 2 days
measure: Comparison of discourse
timeFrame: 2 days
Secondary outcomes:
measure: Comparison of executive scores
timeFrame: 2 days
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Sylvie Moritz-Gasser
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01209208: Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Official title: Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lymphocytic Colitis
Lead sponsor: Dr. Falk Pharma GmbH
Sponsor class: INDUSTRY
First posted: 2010-09-27
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Symptoms and signs of indication of lymphocytic colitis

Exclusion Criteria:

* Infectious diarrhoea,
* Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease
* Pregnancy or breast-feeding,
* Participation in an other clinical trial

Primary outcomes:
measure: Rate of clinical remission
timeFrame: 8 weeks
Secondary outcomes:
measure: Proportion of patients with histological improvement
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf
Study officials:
affiliation: Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg, Germany
name: Stephan Miehlke, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Miehlke S, Aust D, Mihaly E, Armerding P, Bohm G, Bonderup O, Fernandez-Banares F, Kupcinskas J, Munck LK, Rehbehn KU, Nacak T, Greinwald R, Munch A; BUG-1/LMC Study Group. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. Gastroenterology. 2018 Dec;155(6):1795-1804.e3. doi: 10.1053/j.gastro.2018.08.042. Epub 2018 Sep 7.
Clinical trial NCT03910608: Paired Associative Stimulation in Methamphetamine Addiction
Official title: The Mechanisms of Cortico-cortical and Cortico-subcortical Networks in Methamphetamine Addiction by Paired Associative Stimulation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Methamphetamine-dependence
Keywords: Paired Associative Stimulation
Frontoparietal Pathway
Transcranial Magnetic Stimulation
Cognitive Function
Lead sponsor: Shanghai Mental Health Center
Sponsor class: OTHER
First posted: 2019-04-10
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The investigators use paired associative stimulation (PAS) protocols to target cortico-cortical and cortico-subcortical networks to study cognitive deficits in methamphetamine addiction.

Detailed description: Paired associative stimulation (PAS) is a form of transcranial magnetic stimulation in which paired pulses can induce plasticity at cortical synapses, producing long-term potentiation (LTP) or long-term depression (LTD) effect. The investigators use paired associative stimulation (PAS) protocols to target cortico-cortical and cortico-subcortical networks (frontoparietal control pathway) by using different intervals between the paired pulses to explore the mechanism of cognitive deficits in methamphetamine addiction. The investigators hypothesize that different temporal sequences of cortical stimulation could produce facilitation or inhibition effect.

Eligibility criteria: Inclusion Criteria:

* In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders
* Junior high school degree or above
* Normal vision and hearing
* Dextromanual

Exclusion Criteria:

* Have a disease that affect cognitive function such as history of head injury, cerebrovascular disease, epilepsy, etc
* Have cognitive-promoting drugs in the last 6 months
* Other substance abuse or dependence in recent five years (except nicotine)
* Mental impairment, Intelligence Quotient (IQ) \< 70
* Mental disorders
* Physical disease

Primary outcomes:
measure: Change of working memory
timeFrame: 30 minutes
measure: Change of response inhibition
timeFrame: 30 minutes
measure: Change of attention bias
timeFrame: 30 minutes
measure: Change of risk decision
timeFrame: 30 minutes
Secondary outcomes:
measure: Change of eeg oscillatory (Alpha, Beta, Theta and Delta)
timeFrame: 30 minutes
measure: Change of eeg functional connectivity (Alpha, Beta, Theta and Delta)
timeFrame: 30 minutes
measure: Change of motor evoked potential
timeFrame: 30 minutes
measure: Change of resting motor threshold
timeFrame: 30 minutes
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Haifeng Jiang
state: Shanghai
Study officials:
affiliation: Shanghai Mental Health Center
name: Haifeng Jiang, PhD
role: PRINCIPAL_INVESTIGATOR
References: